NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts
NCT07418190 2026-02-18Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical UniversityPhase 2 Recruiting33 enrolled